The Dutch company intends to produce even more Covid-19 test products in North Rhine-Westphalia in the future.
For QIAGEN it is the largest investment program in the company's history: The Dutch-based provider of biological sample and test technologies is investing more than 110 million euros in the expansion of production capacities for coronavirus tests at its sites in Hilden, Barcelona and Maryland.
In addition to expanding capacity, QIAGEN will also expand its portfolio of test solutions. For example, the company is producing a test that can differentiate corona infections from other respiratory diseases. It has also recently launched an antibody test that runs on a portable device and delivers highly accurate results within ten minutes.
The state government of North Rhine-Westphalia is supporting QIAGN to the tune of 18 million euros, which will be used to expand production capacities for corona laboratory diagnostics. "These investments will benefit North Rhine-Westphalia as a business and technology location and will support QIAGEN's growth in Hilden and other locations even after the end of the pandemic," says Roland Sackers, CFO of QIAGEN.
